U.S. Markets open in 8 hrs 35 mins

Benjamin Alouf, M.D., Named Limbix Chief Medical Officer

·2 min read

SAN FRANCISCO, September 02, 2021--(BUSINESS WIRE)--Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced that Benjamin Alouf, M.D., has been named chief medical officer. Dr. Alouf is a board-certified pediatrician with more than two decades of experience overseeing and executing clinical programs and policies.

In his role as CMO, Dr. Alouf will oversee clinical development of SparkRx, a cognitive behavioral therapy-based digital therapeutic program for teens and young adults with symptoms of depression.

"The mental health crisis with young people has reached a tipping point, and I have observed firsthand that teens and young adults increasingly need mental health treatment, yet there are many barriers to them receiving immediate care," said Dr. Alouf. "Not only am I impressed by the clinical rigor with which Limbix is evaluating SparkRx to pursue regulatory pathways, I am energized by the company’s mission to help adolescents with symptoms of depression using digital therapeutics. I see the potential to offer an immediate solution that benefits both providers and patients, and I am incredibly excited and motivated to step into this role and help the company deliver on its vision."

Before joining Limbix, Dr. Alouf served as the chief medical officer at Aetna Better Health of Pennsylvania. Previously, he held leadership positions in large hospital organizations and health plans, as well as faculty positions at Albany Medical College, Thomas Jefferson University, and the Lewis Katz School of Medicine at Temple University.

"Dr. Alouf will be an invaluable asset to the clinical, product and commercialization teams at Limbix, ensuring that our offerings reach and impact patients who are struggling with depression," said Ben Lewis, CEO, Limbix. "As we prepare to make Limbix SparkRx available for authorization by licensed healthcare professionals nationwide, his experience and empathy will be critical in achieving our mission."

About Limbix:

Limbix is a prescription digital therapeutic company passionate about creating mental health treatments for adolescents. The Limbix team is uniquely suited to develop prescription digital therapeutics, as its diverse team of clinicians, product designers, researchers, and engineers understand the value of pairing clinical expertise with technological innovation. Their first digital therapeutic, Limbix SparkRx, will be available this fall for licensed healthcare professionals to offer to patients nationwide.

For more information about Limbix and Limbix SparkRx, please visit limbix.com.

Social Media:

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005243/en/


Liz Boten
Canale Communications